MA54318A - Formulations de capsules - Google Patents

Formulations de capsules

Info

Publication number: MA54318A
Authority: MA; Morocco
Prior art keywords: capsule formulations; capsule; formulations
Prior art date: 2018-11-30

Application number

MA054318A

Other languages

English (en)

Other versions

MA54318B1 (fr

Inventor

Manmohan Reddy Leleti

Jay P Powers

Original Assignee

Chemocentryx Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-11-30

Filing date

2019-11-27

Publication date

2021-10-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70849818&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA54318(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2019-11-27 Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc

2021-10-06 Publication of MA54318A publication Critical patent/MA54318A/fr

2023-08-31 Publication of MA54318B1 publication Critical patent/MA54318B1/fr

Links

239000007963 capsule composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Oil, Petroleum & Natural Gas (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Inorganic Chemistry (AREA)
Immunology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

MA54318A 2018-11-30 2019-11-27 Formulations de capsules MA54318B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201862773848P	2018-11-30	2018-11-30
PCT/US2019/063547 WO2020112961A1 (fr)	2018-11-30	2019-11-27	Formulations de capsules

Publications (2)

Publication Number	Publication Date
MA54318A true MA54318A (fr)	2021-10-06
MA54318B1 MA54318B1 (fr)	2023-08-31

Family

ID=70849818

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MA54318A MA54318B1 (fr)	2018-11-30	2019-11-27	Formulations de capsules
MA62992A MA62992B1 (fr)	2018-11-30	2019-11-27	Formulations de capsules

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
MA62992A MA62992B1 (fr)	2018-11-30	2019-11-27	Formulations de capsules

Country Status (31)

Country	Link
US (4)	US20200170957A1 (fr)
EP (3)	EP4487915A3 (fr)
JP (1)	JP7342124B2 (fr)
KR (1)	KR102586747B1 (fr)
CN (1)	CN113164403A (fr)
AR (1)	AR117219A1 (fr)
AU (1)	AU2019389031B2 (fr)
BR (1)	BR112021010285A2 (fr)
CA (1)	CA3120999C (fr)
CL (1)	CL2021001389A1 (fr)
CY (1)	CY1126079T1 (fr)
DK (2)	DK3886820T3 (fr)
ES (2)	ES2998858T3 (fr)
FI (2)	FI3886820T3 (fr)
HR (2)	HRP20230551T1 (fr)
HU (2)	HUE069633T2 (fr)
IL (1)	IL283450B2 (fr)
LT (2)	LT4233850T (fr)
MA (2)	MA54318B1 (fr)
MD (2)	MD3886820T2 (fr)
MX (1)	MX2021006242A (fr)
NZ (1)	NZ776554A (fr)
PL (2)	PL4233850T3 (fr)
PT (2)	PT4233850T (fr)
RS (2)	RS64250B1 (fr)
SG (1)	SG11202105572UA (fr)
SI (2)	SI4233850T1 (fr)
SM (2)	SMT202400521T1 (fr)
TW (1)	TWI827745B (fr)
WO (1)	WO2020112961A1 (fr)
ZA (1)	ZA202103820B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2020112961A1 (fr)	2018-11-30	2020-06-04	Chemocentryx, Inc.	Formulations de capsules
US11603356B2 (en)	2019-11-08	2023-03-14	Chemocentryx, Inc.	Amorphous form of a complement component C5a receptor
CN116529241A (zh) *	2020-10-28	2023-08-01	坎莫森特里克斯公司	治疗化脓性汗腺炎的方法
JP7839157B2 (ja) *	2020-10-28	2026-04-01	ケモセントリックス，インコーポレイテッド	化膿性汗腺炎を処置する方法
WO2022140258A1 (fr) *	2020-12-21	2022-06-30	Chemocentryx, Inc.	Traitement de la glomérulopathie à c3 à l'aide d'un inhibiteur de c5a
CN119031903A (zh) *	2022-05-19	2024-11-26	陶氏环球技术有限责任公司	基于peg的聚合物间复合物用于改善bcs ii类药物的增溶的用途
WO2025203055A1 (fr) *	2024-03-26	2025-10-02	Council Of Scientific And Industrial Research	Formulation de dihydrofolate encapsulée pour supplémentation alimentaire en tant que supplément nutraceutique efficace et son procédé de préparation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR038681A1 (es) *	2002-02-14	2005-01-26	Solvay Pharm Bv	Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
BRPI0518484A2 (pt)	2004-11-24	2008-11-18	Merck & Co Inc	composiÇço, cÁpsula, e, processo para preparar a mesma
DE102005053066A1 (de)	2005-11-04	2007-05-10	Basf Ag	Verwendung von Copolymeren als Solubilisatoren für in Wasser schwerlöslichen Verbindungen
CA2689137C (fr) *	2007-05-29	2017-05-02	Intrexon Corporation	Ligands diacylhydrazine chiraux destines a moduler l'expression de genes exogenes par le biais d'un complexe recepteur de l'ecdysone
RS54998B1 (sr)	2008-12-22	2016-11-30	Chemocentryx Inc	Antagonisti c5ar
NZ602288A (en) *	2010-03-10	2014-02-28	Abbvie Bahamas Ltd	Solid compositions comprising amorphous (2r,6s,13as,14ar,16as,z)-n-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide
RS56332B1 (sr) *	2010-06-24	2017-12-29	Chemocentryx Inc	Antagonisti c5ar
US9034858B2 (en)	2010-11-30	2015-05-19	Lipocine Inc.	High-strength testosterone undecanoate compositions
US9074470B2 (en)	2010-12-27	2015-07-07	Seven Generations Energy Ltd.	Methods for drilling and stimulating subterranean formations for recovering hydrocarbon and natural gas resources
WO2015118015A1 (fr)	2014-02-05	2015-08-13	Lek Pharmaceuticals D.D.	Compositions pharmaceutiques solides d'antagonistes du récepteur des androgènes
DK3200791T3 (da)	2014-09-29	2020-05-25	Chemocentryx Inc	Fremgangsmåder og mellemprodukter i fremstilling af C5AR- antagonister
JP7339733B2 (ja)	2016-01-14	2023-09-06	ケモセントリックス，インコーポレイティド	Ｃ３腎症を処置する方法
EP3439658B1 (fr)	2016-04-04	2021-11-24	ChemoCentryx, Inc.	Antagonistes de c5ar solubles
TWI826364B (zh)	2017-04-03	2023-12-21	德商因夫萊亞斯有限公司	活性抑制劑於發炎性疾病之治療
CA3077395A1 (fr)	2017-10-30	2019-05-09	Chemocentryx, Inc.	Composes deuteres utilises comme immunomodulateurs
CA3078732A1 (fr)	2017-10-31	2019-05-09	Chemocentryx, Inc.	Reduction par inhibiteur de c5ar du taux urinaire de scd163
US11191756B2 (en)	2018-06-07	2021-12-07	Chemocentryx, Inc.	Dosing and effect of C5a antagonist with ANCA-associated vasculitis
WO2020112961A1 (fr)	2018-11-30	2020-06-04	Chemocentryx, Inc.	Formulations de capsules

2019
- 2019-11-27 WO PCT/US2019/063547 patent/WO2020112961A1/fr not_active Ceased
- 2019-11-27 PT PT231602715T patent/PT4233850T/pt unknown
- 2019-11-27 RS RS20230433A patent/RS64250B1/sr unknown
- 2019-11-27 PL PL23160271.5T patent/PL4233850T3/pl unknown
- 2019-11-27 SI SI201930868T patent/SI4233850T1/sl unknown
- 2019-11-27 MA MA54318A patent/MA54318B1/fr unknown
- 2019-11-27 DK DK19889873.6T patent/DK3886820T3/da active
- 2019-11-27 JP JP2021531035A patent/JP7342124B2/ja active Active
- 2019-11-27 FI FIEP19889873.6T patent/FI3886820T3/fi active
- 2019-11-27 EP EP24196793.4A patent/EP4487915A3/fr active Pending
- 2019-11-27 MD MDE20210972T patent/MD3886820T2/ro unknown
- 2019-11-27 CN CN201980079276.4A patent/CN113164403A/zh active Pending
- 2019-11-27 DK DK23160271.5T patent/DK4233850T3/da active
- 2019-11-27 EP EP23160271.5A patent/EP4233850B1/fr active Active
- 2019-11-27 PL PL19889873.6T patent/PL3886820T3/pl unknown
- 2019-11-27 MA MA62992A patent/MA62992B1/fr unknown
- 2019-11-27 ES ES23160271T patent/ES2998858T3/es active Active
- 2019-11-27 HU HUE23160271A patent/HUE069633T2/hu unknown
- 2019-11-27 SM SM20240521T patent/SMT202400521T1/it unknown
- 2019-11-27 MD MDE20231131T patent/MD4233850T2/ro unknown
- 2019-11-27 NZ NZ776554A patent/NZ776554A/en unknown
- 2019-11-27 EP EP19889873.6A patent/EP3886820B8/fr active Active
- 2019-11-27 AU AU2019389031A patent/AU2019389031B2/en active Active
- 2019-11-27 MX MX2021006242A patent/MX2021006242A/es unknown
- 2019-11-27 LT LTEP23160271.5T patent/LT4233850T/lt unknown
- 2019-11-27 HR HRP20230551TT patent/HRP20230551T1/hr unknown
- 2019-11-27 LT LTEPPCT/US2019/063547T patent/LT3886820T/lt unknown
- 2019-11-27 FI FIEP23160271.5T patent/FI4233850T3/fi active
- 2019-11-27 RS RS20241401A patent/RS66362B1/sr unknown
- 2019-11-27 BR BR112021010285-0A patent/BR112021010285A2/pt not_active Application Discontinuation
- 2019-11-27 IL IL283450A patent/IL283450B2/en unknown
- 2019-11-27 CA CA3120999A patent/CA3120999C/fr active Active
- 2019-11-27 SG SG11202105572UA patent/SG11202105572UA/en unknown
- 2019-11-27 PT PT198898736T patent/PT3886820T/pt unknown
- 2019-11-27 KR KR1020217019883A patent/KR102586747B1/ko active Active
- 2019-11-27 HR HRP20241735TT patent/HRP20241735T1/hr unknown
- 2019-11-27 ES ES19889873T patent/ES2943492T3/es active Active
- 2019-11-27 SM SM20230153T patent/SMT202300153T1/it unknown
- 2019-11-27 US US16/697,523 patent/US20200170957A1/en not_active Abandoned
- 2019-11-27 HU HUE19889873A patent/HUE062551T2/hu unknown
- 2019-11-27 SI SI201930524T patent/SI3886820T1/sl unknown
- 2019-11-29 AR ARP190103505A patent/AR117219A1/es unknown
- 2019-11-29 TW TW108143799A patent/TWI827745B/zh active
2021
- 2021-05-27 CL CL2021001389A patent/CL2021001389A1/es unknown
- 2021-06-03 ZA ZA2021/03820A patent/ZA202103820B/en unknown
- 2021-12-08 US US17/545,878 patent/US11951214B2/en active Active
2023
- 2023-07-03 CY CY20231100309T patent/CY1126079T1/el unknown
2024
- 2024-02-09 US US18/437,368 patent/US20240299306A1/en not_active Abandoned
2025
- 2025-08-28 US US19/313,405 patent/US20250375385A1/en active Pending

Also Published As

Publication number	Publication date
EP4487915A3 (fr)	2025-03-19
SG11202105572UA (en)	2021-06-29
US20220233453A1 (en)	2022-07-28
IL283450A (en)	2021-07-29
HRP20241735T1 (hr)	2025-02-28
IL283450B2 (en)	2024-06-01
WO2020112961A1 (fr)	2020-06-04
US20200170957A1 (en)	2020-06-04
BR112021010285A2 (pt)	2021-08-17
JP2022510304A (ja)	2022-01-26
CN113164403A (zh)	2021-07-23
JP7342124B2 (ja)	2023-09-11
US20240299306A1 (en)	2024-09-12
AU2019389031B2 (en)	2023-06-15
DK3886820T3 (da)	2023-05-15
CA3120999C (fr)	2025-04-01
EP3886820B1 (fr)	2023-04-12
LT3886820T (lt)	2023-06-12
PT3886820T (pt)	2023-05-24
MA62992B1 (fr)	2025-01-31
KR20210098489A (ko)	2021-08-10
MX2021006242A (es)	2021-09-10
EP3886820A4 (fr)	2022-08-24
CY1126079T1 (el)	2023-11-15
MD4233850T2 (ro)	2025-02-28
PL4233850T3 (pl)	2025-03-17
KR102586747B1 (ko)	2023-10-06
MA54318B1 (fr)	2023-08-31
LT4233850T (lt)	2025-01-27
PL3886820T3 (pl)	2023-08-14
EP3886820B8 (fr)	2023-05-17
HUE069633T2 (hu)	2025-04-28
EP4233850A3 (fr)	2023-09-20
HUE062551T2 (hu)	2023-11-28
FI4233850T3 (fi)	2024-12-30
EP3886820A1 (fr)	2021-10-06
ES2943492T3 (es)	2023-06-13
FI3886820T3 (fi)	2023-05-25
RS66362B1 (sr)	2025-01-31
MD3886820T2 (ro)	2023-07-31
ES2998858T3 (en)	2025-02-21
US20250375385A1 (en)	2025-12-11
TW202038952A (zh)	2020-11-01
CA3120999A1 (fr)	2020-06-04
AR117219A1 (es)	2021-07-21
HRP20230551T1 (hr)	2023-08-18
EP4487915A2 (fr)	2025-01-08
SMT202400521T1 (it)	2025-01-14
US11951214B2 (en)	2024-04-09
ZA202103820B (en)	2026-03-25
AU2019389031A1 (en)	2021-06-17
IL283450B1 (en)	2024-02-01
NZ776554A (en)	2024-12-20
DK4233850T3 (da)	2025-01-02
EP4233850B1 (fr)	2024-10-02
SI3886820T1 (sl)	2023-07-31
SMT202300153T1 (it)	2023-09-06
SI4233850T1 (sl)	2025-03-31
TWI827745B (zh)	2024-01-01
RS64250B1 (sr)	2023-06-30
EP4233850A2 (fr)	2023-08-30
CL2021001389A1 (es)	2021-12-24
PT4233850T (pt)	2024-12-30

Publication	Publication Date	Title
MA54318A (fr)	2021-10-06	Formulations de capsules
EP3603642A4 (fr)	2020-09-02	Préparation pharmaceutique
IL285674A (en)	2021-10-31	Pharmaceutical formulations
EP3454847A4 (fr)	2019-12-18	Formulations de médicaments améliorées
EP4340649A4 (fr)	2025-01-22	Capsule
HUE069648T2 (hu)	2025-03-28	Gyógyszerészeti készítmény
IL271908A (en)	2020-02-27	Over-compressed pharmaceutical preparations
PL3787596T3 (pl)	2025-11-12	Ulepszone formulacje farmaceutyczne
EP3706731A4 (fr)	2021-08-18	Formulations améliorées de médicaments
DK3996688T3 (da)	2023-11-27	Farmaceutisk præparat
EP3622941A4 (fr)	2020-12-09	Médicament emballé
ZAA201801557S (en)	2019-08-28	Capsule
ZAA201801556S (en)	2019-08-28	Capsule
PH32018000897S1 (en)	2019-11-08	Capsule
ZAF201800730S (en)	2019-04-24	Capsule
UA34979S (uk)	2017-07-25	Капсула
GB201806710D0 (en)	2018-06-06	Capsule
CL2017001140S1 (es)	2017-08-18	Cápsula
CL2017001145S1 (es)	2017-08-18	Cápsula
CL2017001143S1 (es)	2017-08-18	Cápsula
CL2017001146S1 (es)	2017-08-18	Cápsula
CL2017001142S1 (es)	2017-08-18	Cápsula
CL2017001144S1 (es)	2017-08-18	Cápsula
CL2017001147S1 (es)	2017-09-08	Cápsula
HUE054775T2 (hu)	2021-09-28	Benzidamint tartalmazó gyógyászati készítmény